Preferred Label : Dilpacimab;
NCIt synonyms : DVD-Ig ABT-165; WHO 10863; Immunoglobulin, Anti-(Notch Ligand DLL4/Vascular Endothelial Growth Factor) (Synthetic
Human PR-1283233 Heavy Chain), Disulfide with Synthetic Human PR-1283233 Light Chain,
Dimer;
NCIt definition : A bispecific, tetravalent immunoglobulin (Ig) G-like molecule containing the target-binding
variable domains of two monoclonal antibodies, one targeting the Notch ligand delta-like
4 (DLL4) and the other one targeting the human tyrosine kinase vascular endothelial
growth factor (VEGF), combined via linkers, with potential anti-angiogenic and antineoplastic
activities. Upon administration, dilpacimab targets and binds to both DLL4 and VEGF.
This prevents the activation of DLL-4/Notch- and VEGF/VEGF receptor (VEGFR)-mediated
signaling pathways, which play key roles in angiogenesis and tumor vascularization.
This prevents angiogenesis and may halt tumor cell proliferation. Activation of Notch
receptors by DLL4 stimulates proteolytic cleavage of the Notch intracellular domain
(NICD); after cleavage, NICD is translocated to the nucleus and mediates the transcriptional
regulation of a variety of genes involved in vascular development. The expression
of DLL4 is highly restricted to the vascular endothelium; DLL4/Notch signaling is
required for the development of functional tumor blood vessels. The expression of
the pro-angiogenic growth factor VEGF is associated with tumor angiogenesis and tumor
cell proliferation and invasion.;
UNII : F27LAH6D5O;
CAS number : 1791420-09-1; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 1791420-09-1
alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo
G-SRS /a ;
Molecule name : ABT-165; PR-1283233;
NCI Metathesaurus CUI : CL471747;
Origin ID : C116750;
UMLS CUI : C5235376;
Semantic type(s)
- chemical_or_drug_has_mechanism_of_action
- concept_is_in_subset
- has_target
